Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy-Reference-Cited by-同舟云学术

Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy

Published:2013-07-24 Issue:3 Volume:55 Page:544-550
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Choi Brian S.,Borsaru Gabriela P.,Ballinari Gianluca,Voisin Daniel,Di Renzo Nicola

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2013.813498

Reference26 articles.

1. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update

2. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer

3. Pharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting

4. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist

5. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of netupitant/palonosetron in preventing nausea and vomiting in diffuse large B cell lymphoma patients undergoing R–CHOP chemotherapy;Scientific Reports;2024-05-16

2. Prevention of induced nausea and vomiting in patients with malignant blood disorders. Experience of using netupitant/palonosetron (Akynzeo);MD-Onco;2022-12-14

3. Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin’s lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation;Supportive Care in Cancer;2021-09-17

4. Supportive Drugs in Leukemia Treatment During Pregnancy;Chemotherapy and Pharmacology for Leukemia in Pregnancy;2020-09-27

5. Phase 3 Study of Palonosetron IV Infusion Vs. IV Bolus for Chemotherapy-Induced Nausea and Vomiting Prophylaxis After Highly Emetogenic Chemotherapy;Journal of Pain and Symptom Management;2020-09